BiomX (NYSEMKT:PHGE) Trading Up 22.3% – Still a Buy?

BiomX Inc. (NYSEMKT:PHGE) shot up 22.3% on Monday . The stock traded as high as $0.78 and last traded at $0.90. 53,300 shares were traded during mid-day trading, a decline of 22% from the average session volume of 68,601 shares. The stock had previously closed at $0.74.

BiomX Price Performance

The company has a fifty day simple moving average of $0.73 and a two-hundred day simple moving average of $0.92. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84. The stock has a market capitalization of $16.43 million, a price-to-earnings ratio of -1.21 and a beta of 1.27.

Institutional Investors Weigh In On BiomX

A number of institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. bought a new position in BiomX during the 4th quarter valued at $314,000. Allostery Investments LP bought a new position in shares of BiomX during the fourth quarter valued at about $470,000. Alyeska Investment Group L.P. purchased a new position in BiomX during the fourth quarter worth about $632,000. Finally, Ikarian Capital LLC bought a new stake in BiomX in the 3rd quarter worth about $911,000. Institutional investors and hedge funds own 40.57% of the company’s stock.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.